Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain

Journal of Medicinal Food

Volumn 19, Issue 4, 2016, Pages 374-382

  Kim, Heung Deok ^a   Jeong, Kyoung Hoon ^a   Jung, Un Ju ^b   Kim, Sang Ryong ^a  

^a Kyungpook National University   (South Korea)

^b Pukyong National University   (South Korea)

Author keywords

6 hydroxydopamine; dopaminergic neuron; microglia; myricitrin; neuroprotection

Indexed keywords

BIOFLAVONOID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYRICITRIN; OXIDOPAMINE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; DOPAMINE; FLAVONOID; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; ANIMAL; BRAIN; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PARKINSON DISEASE;

ANIMALS; BRAIN; DOPAMINE; DOPAMINERGIC NEURONS; FLAVONOIDS; HUMANS; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84964681647     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2015.3581     Document Type: Article

References (40)

1. Nussbaum RL, Ellis CE: Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-1364.
2. Savitt JM, Dawson VL, Dawson TM: Diagnosis and treatment of Parkinson disease: Molecules to medicine. J Clin Invest 2006; 116:1744-1754.
3. Block ML, Hong JS: Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol 2005;76:77-98.
4. Qian L, Flood PM: Microglial cells and Parkinson's disease. Immunol Res 2008;41:155-164.
5. Kim SR, Chung ES, Bok E, et al.: Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation. J Neurosci Res 2010;88: 1537-1548.
6. Nam JH, Leem E, Jeon MT, et al.: Inhibition of prothrombin kringle-2-induced inflammation by minocycline protects dopaminergic neurons in the substantia nigra in vivo. Neuroreport 2014;25:489-495.
7. Kim SR, Chen X, Oo TF, et al.: Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol 2011;70:110-120.
8. Kim SR, Kareva T, Yarygina O, Kholodilov N, Burke RE: AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth. Mol Ther 2012;20:275-286.
9. Nam JH, Leem E, Jeon MT, et al.: Induction of GDNF and BDNF by hRheb(S16H) transduction of SNpc neurons: Neuroprotective mechanisms of hRheb(S16H) in a model of Parkinson's disease. Mol Neurobiol 2015;51:487-499.
10. Magalingam KB, Radhakrishnan AK, Haleagrahara N: Protective mechanisms of flavonoids in Parkinson's disease. Oxid Med Cell Longev 2015;2015:314560.
11. Baptista FI, Henriques AG, Silva AM, Wiltfang J, da Cruz e Silva OA: Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. ACS Chem Neurosci 2014;5:83-92.
12. Choi SM, Kim BC, Cho YH, et al.: Effects of flavonoid compounds on b-amyloid-peptide-induced neuronal death in cultured mouse cortical neurons. Chonnam Med J 2014;50: 45-51.
13. Cui QJ, Wang LY, Wei ZX, Qu WS: Continual naringin treatment benefits the recovery of traumatic brain injury in rats through reducing oxidative and inflammatory alterations. Neurochem Res 2014;39:1254-1262.
14. Fu X, Zhang J, Guo L, et al.: Protective role of luteolin against cognitive dysfunction induced by chronic cerebral hypoperfusion in rats. Pharmacol Biochem Behav 2014;126:122-130.
15. Leem E, Nam JH, Jeon MT, et al.: Naringin protects the nigrostriatal dopaminergic projection through induction of GDNF in a neurotoxin model of Parkinson's disease. J Nutr Biochem 2014;25:801-806.
16. Jeong KH, Jeon MT, Kim HD, et al.: Nobiletin protects dopaminergic neurons in the 1-methyl-4-phenylpyridiniumtreated rat model of Parkinson's disease. J Med Food 2015;18: 409-414.
17. Jung UJ, Jeon MT, Choi MS, Kim SR: Silibinin attenuates MPP(+)-induced neurotoxicity in the substantia nigra in vivo. J Med Food 2014;17:599-605.
18. Jung UJ, Leem E, Kim SR: Naringin: A protector of the nigrostriatal dopaminergic projection. Exp Neurobiol 2014;23: 124-129.
19. Chen W, Feng L, Shen Y, et al.: Myricitrin inhibits acrylamidemediated cytotoxicity in human Caco-2 cells by preventing oxidative stress. Biomed Res Int 2013;2013:724183.
20. Asano N, Kuno T, Hirose Y, et al.: Preventive effects of a flavonoid myricitrin on the formation of azoxymethane-induced premalignant lesions in colons of rats. Asian Pac J Cancer Prev 2007;8:73-76.
21. Domitrovic R, Rashed K, Cvijanovic O, Vladimir-Knezevic S, Skoda M, Visnic A: Myricitrin exhibits antioxidant, antiinflammatory and antifibrotic activity in carbon tetrachlorideintoxicated mice. Chem Biol Interact 2015;230:21-29.
22. Qin M, Luo Y, Meng XB, et al.: Myricitrin attenuates endothelial cell apoptosis to prevent atherosclerosis: An insight into PI3K/ Akt activation and STAT3 signaling pathways. Vascul Pharmacol 2015;70:23-34.
23. Wang YH, Yu HT, Pu XP, Du GH: Myricitrin alleviates methylglyoxal-induced mitochondrial dysfunction and AGEs/ RAGE/NF-jB pathway activation in SH-SY5Y cells. J Mol Neurosci 2014;53:562-570.
24. Cai Z, ZengW, Tao K, Lu F, Gao G, Yang Q: Myricitrin alleviates MPP(+)-induced mitochondrial dysfunction in a DJ-1-dependent manner in SN4741 cells. Biochem Biophys Res Commun 2015; 458:227-233.
25. Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW: Tyrosine hydroxylase phosphorylation: Regulation and consequences. J Neurochem 2004;91: 1025-1043.
26. Cordova MM, Werner MF, Silva MD, Ruani AP, Pizzolatti MG, Santos AR: Further antinociceptive effects of myricitrin in chemical models of overt nociception in mice. Neurosci Lett 2011; 495:173-177.
27. Pereira M, Andreatini R, Schwarting RK, Brenes JC: Amphetamine-induced appetitive 50-kHz calls in rats: A marker of affect in mania? Psychopharmacology (Berl) 2014;231: 2567-2577.
28. Park HJ, Lee PH, Ahn YW, et al.: Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci 2007;26:79-89.
29. Chung YC, Kim SR, Jin BK: Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010;185:1230-1237.
30. Royo M, Fitzpatrick PF, Daubner SC: Mutation of regulatory serines of rat tyrosine hydroxylase to glutamate: Effects on enzyme stability and activity. Arch Biochem Biophys 2005;434: 266-274.
31. Datta SR, Brunet A, Greenberg ME: Cellular survival: A play in three Akts. Genes Dev 1999;13:2905-2927.
32. Brunet A, Datta SR, Greenberg ME: Transcription-dependent and-independent control of neuronal survival by the PI3KAkt signaling pathway. Curr Opin Neurobiol 2001;11: 297-305.
33. Timmons S, Coakley MF, Moloney AM, O' Neill C: Akt signal transduction dysfunction in Parkinson's disease. Neurosci Lett 2009;467:30-35.
34. Sato T, Umetsu A, Tamanoi F: Characterization of the RhebmTOR signaling pathway in mammalian cells: Constitutive active mutants of Rheb and mTOR. Methods Enzymol 2008;438: 307-320.
35. Hirsch EC, Hunot S: Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol 2009;8:382-397.
36. Choi SH, Joe EH, Kim SU, Jin BK: Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. J Neurosci 2003;23:5877-5886.
37. Jang SW, Liu X, Yepes M, et al.: A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA 2010;107:2687-2692.
38. Manfredsson FP, Okun MS, Mandel RJ: Gene therapy for neurological disorders: Challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Curr Gene Ther 2009;9:375-388.
39. Shin WH, Jeon MT, Leem E, et al.: Induction of microglial toll-like receptor 4 by prothrombin kringle-2: A potential pathogenic mechanism in Parkinson's disease. Sci Rep 2015;5: 14764.
40. Zhang K, Ma Z, Wang J, Xie A, Xie J: Myricetin attenuated MPP(+)-induced cytotoxicity by anti-oxidation and inhibition of MKK4 and JNK activation in MES23.5 cells. Neuropharmacology 2011;61:329-335